{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:19:53Z","timestamp":1794374393459,"version":"4.9.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:00:00Z","timestamp":1732060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000098","name":"National Institutes of Health Clinical Center","doi-asserted-by":"publisher","award":["Z99CL999999"],"award-info":[{"award-number":["Z99CL999999"]}],"id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jcyt.2024.11.013","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T21:36:38Z","timestamp":1732138598000},"page":"400-409","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy"],"prefix":"10.1016","volume":"27","author":[{"given":"Roshini","family":"Traynor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Vignola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarmila","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Prochazkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongye","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7818-3946","authenticated-orcid":false,"given":"Sarah","family":"Underwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Ramanujam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2746-9410","authenticated-orcid":false,"given":"Sara","family":"Silbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1414-290X","authenticated-orcid":false,"given":"Alexandra","family":"Dreyzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-3265","authenticated-orcid":false,"given":"David F.","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah W.","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0135-0961","authenticated-orcid":false,"given":"Steven L.","family":"Highfill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcyt.2024.11.013_bib0001","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0002","doi-asserted-by":"crossref","first-page":"95ra73","DOI":"10.1126\/scitranslmed.3002842","article-title":"T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia","volume":"3","author":"Kalos","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0003","doi-asserted-by":"crossref","first-page":"4980","DOI":"10.1182\/bloodadvances.2020003844","article-title":"Tisagenlecleucel immunogenicity in relapsed\/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma","volume":"5","author":"Thudium Mueller","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0004","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0005","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0007","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2023.103828","article-title":"Leukapheresis for CAR-T cell production and therapy","volume":"62","author":"Pessach","year":"2023","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.tmrv.2016.03.001","article-title":"CAR-T cell therapies from the transfusion medicine perspective","volume":"30","author":"Fesnak","year":"2016","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0010","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.transci.2018.09.008","article-title":"Risks of leukapheresis and how to manage them\u2014a non-systematic review","volume":"57","author":"Stenzinger","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0011","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","article-title":"Clinical manufacturing of CAR T cells: foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0012","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1479-5876-8-104","article-title":"Comparison of anti-CD3 and anti-CD28-coated beads with soluble anti-CD3 for expanding human T cells: differing impact on CD8 T cell phenotype and responsiveness to restimulation","volume":"8","author":"Li","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0013","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/nm.4241","article-title":"T memory stem cells in health and disease","volume":"23","author":"Gattinoni","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0014","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.1997.15.2.433","article-title":"Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation","volume":"15","author":"Collins","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0015","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0973-6247.106730","article-title":"Adverse events associated with apheresis procedures: incidence and relative frequency","volume":"7","author":"Philip","year":"2013","journal-title":"Asian J Transfus Sci"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0016","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1200\/JOP.0817002","article-title":"Apheresis in the office setting","volume":"4","year":"2008","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0017","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000503937","article-title":"Recommendations for therapeutic apheresis by the section \"preparative and therapeutic hemapheresis\" of the German Society for Transfusion Medicine and Immunohematology","volume":"46","author":"Worel","year":"2019","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0018","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00262-015-1738-9","article-title":"The impact of leukapheresis on immune-cell number and function in patients with advanced cancer","volume":"64","author":"Gulley","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0019","series-title":"Transfusion","article-title":"Sustained decreases in lymphocyte counts in serial long-term leukapheresis donors","author":"Kolf","year":"2003"},{"issue":"1","key":"10.1016\/j.jcyt.2024.11.013_bib0020","first-page":"28","article-title":"Clinical development and manufacture of chimeric antigen receptor t cells and the role of leukapheresis","volume":"13","author":"Fesnak","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0021","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jcyt.2018.11.009","article-title":"Manufacturing chimeric antigen receptor T cells: issues and challenges","volume":"21","author":"Roddie","year":"2019","journal-title":"Cytotherapy"},{"issue":"5","key":"10.1016\/j.jcyt.2024.11.013_bib0022","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/cells9051225","article-title":"Current challenges in providing good leukapheresis products for manufacturing of CAR-T cells for patients with relapsed\/refractory NHL or ALL","volume":"9","author":"Korell","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0023","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)\u2014specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0024","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s43018-024-00749-6","article-title":"Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial","volume":"5","author":"Hegde","year":"2024","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0025","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.22.01214","article-title":"Coadministration of CD19- and CD22-directed chimeric antigen receptor T-cell therapy in childhood B-cell acute lymphoblastic leukemia: a single-arm, multicenter, phase II trial","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0026","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jcyt.2021.07.015","article-title":"Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?","volume":"23","author":"Palen","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0027","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1080\/08830185.2022.2067154","article-title":"Scaling up and scaling out: advances and challenges in manufacturing engineered T cell therapies","volume":"41","author":"Song","year":"2022","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0028","doi-asserted-by":"crossref","first-page":"eadn1902","DOI":"10.1126\/scitranslmed.adn1902","article-title":"The translational gap for gene therapies in low- and middle-income countries","volume":"16","author":"Doxzen","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0029","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jcyt.2017.06.009","article-title":"A roadmap for cost-of-goods planning to guide economic production of cell therapy products","volume":"19","author":"Lipsitz","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0030","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.jcyt.2024.11.013_bib0031","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.3747\/co.27.5283","article-title":"Chimeric antigen receptor T cell therapy comes to clinical practice","volume":"27","author":"Wall","year":"2020","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0032","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0033","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.omto.2018.10.006","article-title":"Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22","volume":"11","author":"Qin","year":"2018","journal-title":"Mol Ther\u2014Oncolytics"},{"key":"10.1016\/j.jcyt.2024.11.013_bib0034","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.2022015795","article-title":"CD19\/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR","volume":"140","author":"Shalabi","year":"2022","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324924009393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:09:20Z","timestamp":1762546160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324924009393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1465324924009393"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.013","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient manufacturing of CAR-T cells from whole blood: a scalable approach to reduce costs and enhance accessibility in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2024.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society for Cell & Gene Therapy.","name":"copyright","label":"Copyright"}]}}